Neurocrine Biosciences, Inc.
603 articles about Neurocrine Biosciences, Inc.
-
Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference 2023
11/8/2023
Neurocrine Biosciences, Inc. will present at the Jefferies London Healthcare Conference on Tuesday November 14, 2023 at 3:00 p.m. Greenwich Mean Time in London.
-
Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
11/8/2023
Neurocrine Biosciences, Inc. announced the availability of DISCOVER TD™, an interactive digital tool designed to help healthcare providers learn about and identify tardive dyskinesia.
-
In a late-stage study, most Huntington’s disease patients reported that their symptoms of chorea were “much improved” or “very much improved” following treatment with Neurocrine Biosciences’ VMAT2 inhibitor Ingrezza.
-
Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023
11/2/2023
Neurocrine Biosciences, Inc. announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® capsules when used for the long-term treatment of adults with chorea associated with Huntington's disease.
-
Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
10/31/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2023, raised 2023 net sales guidance for INGREZZA, and announced an Analyst Day to be held in New York City on December 5th.
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results
10/10/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on October 31, 2023.
-
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
10/5/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Pediatric Study evaluating the efficacy, safety, and tolerability of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
-
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023
9/21/2023
Neurocrine Biosciences, Inc., announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug crinecerfont in adolescent patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
-
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
9/14/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for INGREZZA ® (valbenazine) oral granules, a new sprinkle formulation of INGREZZA.
-
Topline data for the company’s CRF1 antagonist crinecerfont showed a significant drop in daily glucocorticoid dose, while maintaining androgen control in adult patients with the genetic disorder.
-
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
9/12/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).
-
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
9/11/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117570 in healthy adult participants.
-
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
8/31/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in September. Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla, Vice President of Investor Relations, will present at the 2023 Wells Fargo Healthcare Conference at 3:45 p.m. Eastern Time on Thursday, September 7, 2023 in Boston.
-
Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in TD Severity and Impact Following Treatment With INGREZZA® (valbenazine) Capsules
8/29/2023
Neurocrine Biosciences, Inc. presented findings from a data analysis of KINECT®-4 demonstrating a comparable pattern of improvement over time of clinician-rated tardive dyskinesia severity and awareness/distress as measured by the Abnormal Involuntary Movement Scale and patient-reported TD impact as measured by the Trajectories of Tardive Dyskinesia Impact Scale.
-
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease
8/28/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD), including exploratory results from the Phase 3 KINECT®-HD study, which showed consistently greater improvements in HD chorea with INGREZZA versus placebo from Week 2 to Week 12.
-
Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease
8/18/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD).
-
The FDA has four decisions on deck this week, including ones for two rare disease treatments from Ipsen and Regeneron.
-
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
8/1/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2023 and raised net sales guidance for INGREZZA in 2023.
-
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results
7/11/2023
Neurocrine Biosciences, Inc. announced that it has scheduled its second quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time on August 1, 2023.
-
Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors
7/11/2023
Neurocrine Biosciences, Inc. announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors.